Table 1.
Demographics, disease characteristics, and follow‐up of the Austrian alemtuzumab cohort.
| n = 87 | % | |
|---|---|---|
| Female; No. | 63 | 72 |
| Age at MS diagnosis, y; median (IQR) | 26 (21–31) | |
| Age at ALEM start, y; median (IQR) | 32 (26–36) | |
| Disease duration, y; median (IQR) | 5 (1–11) | |
| RRMS; No. | 87 | 100 |
| ARR in the 12 months before ALEM; mean (95% CI) | 1.2 (0.8–1.8) | |
| EDSS; median (IQR) | 2.5 (1.8–3.5) | |
| Naïve to DMTs; No. | 12 | 14 |
| No. of previous DMTs; median (range) | 1 (0–3) | |
| No. of patients with prior high‐efficacy DMTs | 50 | 58 |
| No. patients switched from NAT | 16 | 18 |
| No. patients switched from FTY | 31 | 36 |
| No. of patients throughout the follow‐up | ||
| At month 24 | 81 | 93 |
| At month 48 | 62 | 71 |
| At month 72 | 31 | 36 |
| At month 96 | 7 | 8 |
ALEM, alemtuzumab; ARR, annualized relapse rate; CI, confidence interval; DMTs, disease‐modifying therapies; EDSS, expanded disability status scale; FTY, fingolimod; IQR, interquartile range; MS, multiple sclerosis; NAT, natalizumab; No., number of; RRMS, relapsing–remitting multiple sclerosis; y, years.